Clinical date
A total of 474 patients with colorectal cancer attending the Department of Oncology of the Second Affiliated Hospital of Air Force Military Medical University from October 2019 to February 2023 were initially included in this study, and those with one of the following conditions were excluded by the exclusion criteria: (1) patients without a definitive pathological diagnosis; (2) patients receiving postoperative adjuvant chemotherapy or regular follow-up; (3) patients without target lesions who cannot be evaluated for RESIST 1.1; (4) patients with advanced colorectal cancer receiving first-line treatment at first diagnosis; (5) patients with a combination of 2 or more malignancies; (6) end-stage patients receiving palliative symptomatic supportive care; (7) patients with unsuccessful follow-up or incomplete case data. Finally, 127 patients were included, 87 males; 40 females; the age range was 41-81 years old, with a median age of 60 years; there were 65 patients who received immune checkpoint inhibitors(ICI) and 62 patients who did not receive immune checkpoint inhibitors; 84 cases of left colon cancer (including left transverse colon, descending colon, and sigmoid colon), and 43 cases of right colon cancer (including cecum, ascending colon, and right transverse colon); 9 cases of patients with dMMR, and 118 cases of patients with pMMR; 63 cases of patients with KRAS mutant type, and 64 cases of patients with KRAS wild type; 86 cases of patients who combined targeted therapy in the course of treatment, 41 cases of patients who did not combine targeted therapy, specific detailed data are shown in Table 1.
Table 1 Patient Characteristics